Treatment of multiple sclerosis with interferon β1b

被引:0
|
作者
Dhib-Jalbut, S
McFarland, HF
机构
[1] Univ Maryland Hosp, Dept Neurol, Baltimore, MD 21201 USA
[2] NINCDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
来源
BAILLIERES CLINICAL NEUROLOGY | 1997年 / 6卷 / 03期
关键词
interferon beta(1b); Betaseron; multiple sclerosis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interferon beta(1b) is now an established therapeutic option for relapsing remitting multiple sclerosis. More recently, it has also been shown to slow down disease progression in secondary progressive multiple sclerosis. Interferon beta(1b)'s clinical effect is reflected in MRI studies demonstrating a dramatic effect in reducing disease activity. The drug is generally well tolerated, but its efficacy can be compromised in some patients by the emergence of neutralizing antibodies. This chapter will focus on interferon beta(1b) (Betaseron) treatment for multiple sclerosis, its clinical and MRI effects, and its putative mechanism of action.
引用
收藏
页码:467 / 480
页数:14
相关论文
共 50 条
  • [31] Predictors of clinical response to interferon?1b therapy in patients with multiple sclerosis
    Hosokawa, T.
    Nakajima, H.
    Ikemoto, T.
    Sugino, M.
    Kimura, F.
    Hanafusa, T.
    Takahashi, T.
    MULTIPLE SCLEROSIS, 2009, 15 (01): : 144 - 144
  • [32] The distribution of magnetic resonance imaging response to interferonβ-1b in multiple sclerosis
    Sormani, MP
    Bruzzi, P
    Beckmann, K
    Kappos, L
    Miller, DH
    Polman, C
    Pozzilli, C
    Thompson, AJ
    Wagner, K
    Filippi, M
    JOURNAL OF NEUROLOGY, 2005, 252 (12) : 1455 - 1458
  • [33] Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b
    Sridar Narayanan
    Nicola De Stefano
    Gordon S. Francis
    Rozie Arnaoutelis
    Zografos Caramanos
    D. Louis Collins
    Daniel Pelletier
    Barry G. W. Arnason
    Jack P. Antel
    Douglas L. Arnold
    Journal of Neurology, 2001, 248 : 979 - 986
  • [34] The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis
    M. P. Sormani
    P. Bruzzi
    K. Beckmann
    L. Kappos
    D. H. Miller
    C. Polman
    C. Pozzilli
    A. J. Thompson
    K. Wagner
    M. Filippi
    Journal of Neurology, 2005, 252 : 1455 - 1458
  • [35] Interferon β-1b in Therapy of Multiple Sclerosis: Experience, Innovation and Options for Future
    Gold, R.
    Linker, R.
    AKTUELLE NEUROLOGIE, 2009, 36 : S227 - S227
  • [36] Use of interferon beta 1b for multiple sclerosis - Manufacturer defends the drug
    Longthorne, PN
    BRITISH MEDICAL JOURNAL, 1996, 313 (7067): : 1263 - 1263
  • [37] Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis
    Goodin, D. S.
    Hurwitz, B.
    Noronha, A.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2007, 35 (02) : 173 - 187
  • [38] Response to beta interferon 1b among Saudi patients with multiple sclerosis
    Kargwell, H
    Yaqub, BA
    Al-Deeb, SM
    SAUDI MEDICAL JOURNAL, 2003, 24 (01) : 44 - 48
  • [39] Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis
    Modrego, P. J.
    Gazulla, J.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1655 - 1656
  • [40] Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b
    Narayanan, S
    De Stefano, N
    Francis, GS
    Arnaoutelis, R
    Caramanos, Z
    Collins, DL
    Pelletier, D
    Arnason, BGW
    Antel, JP
    Arnold, DL
    JOURNAL OF NEUROLOGY, 2001, 248 (11) : 979 - 986